MONDAY, July 19, 2021 (HealthDay News) — What’s better — a long life or quality of life? New research suggests that people balance both when thinking about their desired life span, and fears of suffering dementia or chronic pain in old age tend to limit how long they want toContinue Reading
THURSDAY, July 15, 2021 (HealthDay News) — Two major U.S. health systems say they will not administer the controversial new Alzheimer’s drug Aduhelm. The decisions by the Cleveland Clinic and Mount Sinai’s Health System in New York City are the latest fallout from the U.S. Food and Drug Administration’s widelyContinue Reading
THURSDAY, July 15, 2021 (HealthDay News) — An active mind in old age may delay Alzheimer’s disease by up to five years, a new study suggests. Activities like reading, writing letters, playing cards or doing puzzles may prolong brain health even for those in their 80s, researchers say. “The keyContinue Reading
TUESDAY, July 13, 2021 (Healthday News) — Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer’s drug whose high price tag and unproven benefits have prompted widespread controversy. Medicare’s announcement came the same day that leaders of two HouseContinue Reading
MONDAY, July 12, 2021 (Healthday News) — The U.S. Food and Drug Administration’s controversial approval of the Alzheimer’s drug Aduhelm should be investigated by the Office of Inspector General (OIG), FDA Acting Commissioner Dr. Janet Woodcock has said. The FDA approved Aduhelm even though an advisory panel of outside expertsContinue Reading
THURSDAY, July 8, 2021 (HealthDay News) — The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer’s medication Aduhelm that will likely limit its use. When first approved a month ago, the FDA said Biogen’s monthly IV drug was for all Alzheimer’s patients. TheContinue Reading
THURSDAY, July 1, 2021 (Healthday News) — The U.S. Food and Drug Administration’s controversial approval of a new Alzheimer’s drug, along with its high price, is now being investigated by two House committees. “We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the processContinue Reading
TUESDAY, June 29, 2021 (HealthDay News) — Dementia patients who have the same nurse for all of their home health care visits are a third less likely to be readmitted to the hospital, a new study finds. “While continuity of nursing care may benefit every home health care patient, itContinue Reading
MONDAY, June 28, 2021 (HealthDay News) — Most Americans with dementia are undiagnosed, which shows how important it is to screen and assess seniors for the disease, researchers say. Their new analysis of data from a nationwide survey of about 6 million Americans aged 65 and older revealed that 91%Continue Reading
FRIDAY, June 25, 2021 (Healthday News) — Fresh on the heels of the U.S. Food and Drug Administration’s approval of the controversial Alzheimer’s drug Aduhelm, the maker of a second medicine that works in similar fashion said Thursday it hopes to apply for approval of its medication later this year.Continue Reading